Retrospective evaluation of interventional treatment of peripheral slow-flow malformations using image-guided bleomycin electrotherapy.

Recruiting

• Conditions: Q89; Other congenital malformations, not elsewhere classified

• Registration Number: DRKS00031072
• Lead Sponsor: MU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients with a diagnosis of combined slow-flow peripheral vascular malformation (capillary-venous malformation, CVM; capillary-lymphatic malformation, CLM; lymphatic-venous malformation, LVM; capillary-lymphatic-venous malformation, CLVM) and who have undergone imaging-guided treatment by a Bleomycin electro-sclerotherapy (BEST) in the form of one or more sessions in the period from 01.01.2020 to 30.12.2022

Exclusion Criteria

Patients with other vascular anomalies (high-flow malformations) or vascular tumors
Patients who have received the above procedures with other image-guided sclerotherapy/embolization techniques, e.g. B. Polidocanol sclerotherapy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analysis of the complication rate after interventional treatment using image-guided bleomycin electro-sclerotherapy (BEST) of simple or mixed peripheral slow-flow malformations (peri-interventional and post-interventional complications < 30 days)

Secondary Outcome Measures

Name	Time	Method
Analysis of the technical success after interventional treatment using image-guided bleomycin electro-sclerotherapy (BEST) of simple or mixed peripheral slow-flow malformations (successful execution of the interventions)